Judith Haschka 1,2, Jürgen Rech 3, Matthias Englbrecht 1, Stephanie Finzel 1, Michaela Reiser 1, Axel J. 2014 ACR/ARHP Annual Meeting Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission.
![tchia litman therapy tchia litman therapy](https://i.pinimg.com/originals/aa/ce/61/aace61a207a1c1b534a54f9dcacc5cf6.jpg)
Little is known about the role of different mode…
![tchia litman therapy tchia litman therapy](https://discountcardiology.com/images/P/3M-LITTMANN-CARDIOLOGY-III-STETHOSCOPE-27%2C-Black-Tubing%2C-Brass-Finish-01.jpg)
of Clinical Sciences, Malmö, Sweden, 3Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, 4Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 5Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden Background/Purpose: About 30% of patients receiving biologic therapy do not have concomitant conventional synthetic DMARDs (csDMARDs). Kapetanovic 3, Martin Englund 4,5, Aleksandra Turkiewicz 4, Robin Christensen 1, Henning Bliddal 1, Pierre Geborek 3 and Lars Erik Kristensen 1, 1The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, 2Lund University, Rheumatology, Dept. Tanja Schjødt Jørgensen 1, Carl Turesson 2, Meliha C. 2015 ACR/ARHP Annual Meeting Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry.Cannon 7, 1IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 2HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 3Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 4University of Nebraska Medical Center, Omaha, NE, 5University of Alabama at Birmingham, Birmingham, AL, 6Amgen, Inc., Thousand Oaks, CA, 7Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate + hydroxychloroquine + sulfasalazine ) and tumor necrosis factor… 2015 ACR/ARHP Annual Meeting Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritisīrian Sauer 1, Chia-Chen Teng 2, Jianwei Leng 3, Ted R.